| 2026-08-12 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-05 | Press release | Travere Therapeutics to Participate at Upcoming Investor Conferences |
| 2026-08-04 | Supplement | Investor Fact Sheet |
| 2026-08-04 | Press release | Press release · Q2 2026 · Aug 2026 |
| 2026-08-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-04 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-28 | Press release | Travere Therapeutics to Report Second Quarter 2026 Financial Results |
| 2026-07-10 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-10 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-09 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-16 | Press release | Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027 |
| 2026-06-16 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-11 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-10 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-04 | Press release | View PDF , Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd E |
| 2026-06-02 | Press release | Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases |
| 2026-06-02 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-27 | Press release | Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy |
| 2026-05-21 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-13 | Press release | Travere Therapeutics to Participate at Upcoming Investor Conferences |
| 2026-05-12 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-11 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-10 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-07 | Press release | View PDF , Travere Therapeutics to Participate at Upcoming Investor Conferences |
| 2026-05-06 | Press release | View PDF , Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes |
| 2026-05-05 | Press release | Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes |
| 2026-05-04 | Press release | Travere Therapeutics Reports First Quarter 2026 Financial Results |
| 2026-05-04 | Supplement | Investor Fact Sheet of Q1 2026 |
| 2026-05-04 | Press release | Press Release of Q1 2026 |
| 2026-05-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-04 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-27 | Press release | Travere Therapeutics to Report First Quarter 2026 Financial Results |
| 2026-04-14 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-14 | 8-K | Form 8-K, Item 8.01 |
| 2026-04-13 | Press release | View PDF , Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medic |
| 2026-04-06 | Proxy | Definitive proxy statement |
| 2026-02-21 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-19 | Press release | Press release · FY 2025 · Feb 2026 |
| 2026-02-19 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-19 | 10-K | Annual report on Form 10-K, FY25 |